Cefazolin dosing protocol for patients receiving long-term hemodialysis

American Journal of Health-System Pharmacy

Volumn 60, Issue 2, 2003, Pages 178-181

  Ahern, John W ^a   Possidente, Carl J ^b   Hood, Virginia ^a,c   Kemper Alston, W ^a  

^a FLETCHER ALLEN HEALTH CARE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS MEMBRANE; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MALE; NOTE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0037439411     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.2.178     Document Type: Note

References (11)

1. Wilhelm MP, Estes L. Vancomycin. Mayo Clin Proc. 1999; 74:928-35.
2. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999; 340:493-501.
3. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin United States. MMWR Morb Mortal Wkly Rep. 1997; 46:813-5.
4. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. MMWR Morb Mortal Wkly Rep. 1995; 44:1-13.
5. Tokars JI. Vancomycin use and antimicrobial resistance in hemodialysis centers. Am J Kidney Dis. 1998; 32:521-3. Editorial.
6. Sowinski KM, Mueller BA, Grabe DW et al. Cefazolin dialytic clearance by highefficiency and high-flux hemodialyzers. Am J Kidney Dis. 2001; 37:766-76.
7. Marx MA, Frye RF, Matzke GR et al. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis. 1998; 32:410-4.
8. Fogel MA, Nussbaum PB, Feintzeig ID et al. Cefazolin in chronic hemodialysis patients: a safe, effective, alternative to vancomycin. Am J Kidney Dis. 1998; 32:401-9.
9. Kuypers D, Vanwalleghem J, Maes B et al. Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment. Nephrol Dial Transplant. 1999; 14:2050-1. Letter.
10. Drabik TE, Foote EF, Melendez O et al. Pharmacokinetics of cefazolin during high-flux hemodialysis in patients with residual renal function. J Am Soc Nephrol. 1999; 10:A0970. Abstract.
11. Performance standards for antimicrobial susceptibility testing; eleventh informational supplement. Document M100-S11. Wayne, PA: NCCLS; 2001.